Corpus ID: 34066946

Update on methotrexate as the anchor drug for rheumatoid arthritis.

@article{Pincus2013UpdateOM,
  title={Update on methotrexate as the anchor drug for rheumatoid arthritis.},
  author={T. Pincus and K. Gibson and I. Castrejon},
  journal={Bulletin of the Hospital for Joint Disease},
  year={2013},
  volume={71 Suppl 1},
  pages={
          S9-19
        }
}
  • T. Pincus, K. Gibson, I. Castrejon
  • Published 2013
  • Medicine
  • Bulletin of the Hospital for Joint Disease
  • Methotrexate has become the "anchor drug" for rheumatoid arthritis (RA), taken by many more patients than any other disease modifying anti-rheumatic drug (DMARD) or biological agent. Methotrexate has greater efficacy and effectiveness than any other non-biologic DMARD, and greater tolerability and safety than other DMARDs. The efficacy of methotrexate is comparable to biologic agents in parallel clinical trials of DMARD-naïve patients. Adequate responses to methotrexate monotherapy or… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Biologic monotherapy in the treatment of rheumatoid arthritis
    • 22
    • Open Access
    Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis
    • 20
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 90 REFERENCES